Yuka Iijima‐Yamashita
A5049685204- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Chronic Myeloid Leukemia Treatments
- Hematopoietic Stem Cell Transplantation
- Childhood Cancer Survivors' Quality of Life
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Retinoids in leukemia and cellular processes
- Chronic Lymphocytic Leukemia Research
- Immune Cell Function and Interaction
- Hemoglobinopathies and Related Disorders
- CAR-T cell therapy research
- CRISPR and Genetic Engineering
- Gene expression and cancer classification
- Cancer-related Molecular Pathways
- Cancer Immunotherapy and Biomarkers
- Neutropenia and Cancer Infections
- Blood disorders and treatments
- Molecular Biology Techniques and Applications
- Protein Degradation and Inhibitors
- Lung Cancer Research Studies
- Cytomegalovirus and herpesvirus research
- Adolescent and Pediatric Healthcare
- Drug-Induced Ocular Toxicity
Nagoya Medical Center
2017-2024
National Hospital Organization
2017-2023
Abstract Germ line DDX41 variants have been implicated in late-onset myeloid neoplasms (MNs). Despite an increasing number of publications, many important features DDX41-mutated MNs remain to be elucidated. Here we performed a comprehensive characterization MNs, enrolling total 346 patients with pathogenic/likely-pathogenic (P/LP) germ and/or somatic mutations from 9082 MN patients, together 525 first-degree relatives and wild-type (WT) patients. P/LP explained ∼80% known predisposition...
Abstract Recent genetic studies using high-throughput sequencing have disclosed alterations in B-cell precursor acute lymphoblastic leukemia (B-ALL). However, their effects on clinical outcomes not been fully investigated. To address this, we comprehensively examined and prognostic impact a large series of pediatric B-ALL cases. We performed targeted capture total 1003 patients with from 2 Japanese cohorts. Transcriptome (n = 116) and/or array-based gene expression analysis 120) were also...
Abstract In childhood acute lymphoblastic leukemia (ALL), TP53 gene mutation is associated with chemoresistance in a certain population of relapsed cases. To directly verify the association ALL cases and improve their prognosis, development appropriate human models having intrinsic required. Here, we sought to introduce R248Q hotspot into an cell line, 697, by applying prime editing (PE) system, which versatile genome technology. The PE2 system uses artificial fusion nickase Cas9...
The JCCG ALL-B12 clinical trial aimed to evaluate the effectiveness of unvalidated treatment phases for pediatric ALL and develop a safety-focused framework.
Abstract Background In acute myeloid leukemia ( AML ), accurate detection of minimal residual disease MRD ) enables better risk‐stratified therapy. There are few studies, however, on the monitoring multiple fusion transcripts and evaluation their accuracy as indicators at time points. Methods We retrospectively examined RNA obtained from 82 pediatric patients enrolled in Japanese Pediatric Leukemia/Lymphoma Study Group JPLSG ‐05 study. The expression six important 1( RUNX 1)‐ ETO , CBFB ‐...
Gene abnormalities, particularly chromosome rearrangements generating gene fusion, are associated with clinical characteristics and prognosis in pediatric acute myeloid leukemia (AML). Karyotyping is generally performed to enable risk stratification, but the results not always consistent those of reverse transcription-polymerase chain reaction (RT-PCR), more accurate rapid methods required.A total 487 samples from de novo AML patients enrolled Japanese Pediatric Leukemia/Lymphoma Study Group...
CD25 is an aberrant marker expressed on the leukemic stem cell (LSC) surface and immunotherapy target in acute myeloid leukemia (AML). However, clinical prevalence significance of expression pediatric AML are unknown. High IL2RA/CD25 showed a cell-like phenotype, elevated was associated with lower overall survival (p < .001) event-free Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 study. This finding reproduced without core-binding factor Children's Oncology study cohort. has...
There is no established treatment for patients with acute promyelocytic leukemia (APL) refractory to targeted therapies all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO). We report here a case of an 8-month-old girl APL who failed standard ATRA-combined chemotherapy. Although molecular remission was achieved after introducing ATRA/ATO combination therapy, relapse occurred during the ATO consolidation courses. Subsequent rapidly administering 2 doses gemtuzumab ozogamicin. She...